- Report
- May 2023
- 100 Pages
Global
From €5754EUR$5,950USD£4,873GBP
- Report
- September 2023
- 115 Pages
Global
From €5319EUR$5,500USD£4,504GBP
- Report
- March 2024
- 188 Pages
Global
From €3263EUR$3,374USD£2,763GBP
€3625EUR$3,749USD£3,070GBP
- Report
- October 2023
- 146 Pages
Global
From €2417EUR$2,499USD£2,047GBP
- Report
- March 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,095GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,095GBP
- Report
- February 2024
- 175 Pages
Global
From €4835EUR$5,000USD£4,095GBP
- Report
- January 2024
- 149 Pages
Global
From €3771EUR$3,899USD£3,193GBP
- Report
- June 2023
- 71 Pages
Global
From €4787EUR$4,950USD£4,054GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1209EUR$1,250USD£1,024GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1209EUR$1,250USD£1,024GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1209EUR$1,250USD£1,024GBP
- Clinical Trials
- April 2024
- 85 Pages
Global
From €1934EUR$2,000USD£1,638GBP
- Clinical Trials
- February 2024
- 60 Pages
Global
From €1209EUR$1,250USD£1,024GBP
- Report
- November 2023
- 180 Pages
Global
From €4739EUR$4,900USD£4,013GBP
- Report
- October 2023
- 255 Pages
Global
From €4637EUR$4,795USD£3,927GBP
- Report
- March 2024
- 76 Pages
Global
From €2853EUR$2,950USD£2,416GBP
- Report
- March 2024
- 123 Pages
Global
From €4787EUR$4,950USD£4,054GBP
- Report
- June 2023
- 60 Pages
United States
From €5754EUR$5,950USD£4,873GBP
- Report
- October 2023
- 89 Pages
United States
From €4739EUR$4,900USD£4,013GBP
Schizophrenia is a mental disorder characterized by abnormal social behavior and a distorted perception of reality. It is one of the most disabling and emotionally devastating mental illnesses, affecting approximately 1% of the population worldwide. Symptoms of schizophrenia can include hallucinations, delusions, disorganized speech and behavior, and cognitive deficits.
The schizophrenia market within the context of mental health is a rapidly growing sector, driven by the increasing prevalence of the disorder and the need for better treatments. The market is expected to benefit from the development of novel drugs and therapies, as well as the increasing awareness of mental health issues. Additionally, the increasing focus on personalized medicine and the development of digital health technologies are expected to drive the market growth.
Some of the key players in the schizophrenia market include Eli Lilly, Johnson & Johnson, Novartis, Pfizer, Otsuka Pharmaceutical, Sunovion Pharmaceuticals, Allergan, and Merck. Show Less Read more